Fish oils again under the spotlight

otcinaction

As reported in our newly published Q2 2019 update, herbal & natural supplements are performing well, up 4.4% globally, thanks to a revival in sales in North America that is partly powered by a return to growth for fish oils & omega-3. This well-developed OTC subcategory generates close to US$2bn in global sales, and after two years of decline in 2015 and 2016, turnover has been rising slowly but surely in recent years. An article that appeared in the New York Times over the weekend, however, entitled Should I Take Fish Oil?, has the potential to halt these gains.

Describing the results of omega-3 studies so far as “inconclusive and inconsistent”, the article calls for further large-scale scientific trials, such as the recent VITAL study, which found that omega-3 supplements didn’t reduce the risk of major cardiac events in a usual-risk population, but did reduce the risk in a subset of people with low fish intake by 19%. The article also pointed to environmental concerns about the fish reduction industry, advocating for vegan and algae-based omega-3 supplements instead.

FISH OILS.png

The Council for Responsible Nutrition (CRN) and other industry bodies, like the Global Organization for EPA and DHA Omega-3 (GOED), are obviously concerned about this article and its ramifications for the fish oils market. One thing worth emphasising about the article is that it doesn’t discount the importance of omega-3 fatty acids as essential nutrients and it doesn’t change the current recommendations by authoritative sources who support intake of omega-3 fatty acids for maintaining overall health.

According to the 2015–2020 Dietary Guidelines for Americans, people should aim to consume eight or more ounces of seafood per week, especially fatty fish, however the reality is that the majority of people don’t manage to achieve this through their diet. For many consumers, especially those with a low fish intake, taking omega-3 fatty acid supplements remains the most prudent choice to ensure the adequate levels needed for good health.

Only two weeks to go until Nicholas Hall’s OTC.NewDirections Executive Conferencetaking place in London on 14 November 2019! Nicholas will be joined by experts from companies including Bayer, Mundipharma and J&J to review key issues impacting our industry and ensure that you are Keeping Consumers in the Spotlight. Unable to join us? Watch Nicholas’ opening address live on the day here at 09:05 on 14 November. To experience the event in full, you can book your place or find out more by contacting jennifer.odonnell@NicholasHall.com without delay.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s